[HTML][HTML] Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma
T Chen, L Liu, Y Zou, X Hu, W Zhang… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: Natural extracts, including nobiletin, have been reported to enhance the efficacy
and sensitivity of chemotherapeutic drugs. However, whether and how nobiletin affects …
and sensitivity of chemotherapeutic drugs. However, whether and how nobiletin affects …
[HTML][HTML] Nobiletin Inhibits Cell Viability via the SRC/AKT/STAT3/YY1AP1 Pathway in Human Renal Carcinoma Cells
D Wei, G Zhang, Z Zhu, Y Zheng, F Yan… - Frontiers in …, 2019 - frontiersin.org
Nobiletin is a polymethoxy flavonoid isolated from Citrus depressa and Citrus reticulata. It
has been reported that nobiletin can suppress tumors. We primarily explored the antitumor …
has been reported that nobiletin can suppress tumors. We primarily explored the antitumor …
Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway
Z Xu, D Wu, D Fu, C Tang, J Ge, Z Zhang… - Cellular and Molecular …, 2020 - cellmolbiol.org
Nobiletin, a flavonoid found chiefly in oranges and lemons, has exhibited potential anti-
proliferative and pro-apoptotic activities in various types of cancers. However, the inhibitory …
proliferative and pro-apoptotic activities in various types of cancers. However, the inhibitory …
[HTML][HTML] Nobiletin suppresses cholangiocarcinoma proliferation via inhibiting GSK3β
L You, J Lin, Z Yu, Y Qian, Y Bi, F Wang… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Background: Cholangiocarcinoma (CCA) is a type of hepatobiliary cancer characterized by
uncontrolled cell proliferation, with a poor prognosis and high mortality. Nobiletin (NBT) is a …
uncontrolled cell proliferation, with a poor prognosis and high mortality. Nobiletin (NBT) is a …
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
Background Immunotherapy is a standard-of-care first-line treatment for advanced clear cell
renal cell carcinoma (ccRCC). However, many patients will develop resistance to first-line …
renal cell carcinoma (ccRCC). However, many patients will develop resistance to first-line …
Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cells
J Li, R Ma, J Lv, Y Ren, Y Tan, H Wang, Z Wang… - Phytomedicine, 2024 - Elsevier
Background The high metastasis and mortality rates of Head and neck squamous cell
carcinoma (HNSCC) urgently require new treatment targets and drugs. A steroidal …
carcinoma (HNSCC) urgently require new treatment targets and drugs. A steroidal …
Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak. Bcl-xl complex
G Zhang, L Li, J Li, P Li, S Zeng, H Sun, E Li - Biochemical pharmacology, 2019 - Elsevier
Palbociclib is a Cdk4/6 inhibitor approved for metastatic estrogen receptor-positive breast
cancer. The drug is also under clinical evaluation for metastatic urothelial cancer and other …
cancer. The drug is also under clinical evaluation for metastatic urothelial cancer and other …
[HTML][HTML] Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells
X Yu, F Liu, L Zeng, F He, R Zhang, S Yan… - Cellular Physiology and …, 2018 - karger.com
Background/Aims: As the most lethal urological cancers, renal cell carcinoma (RCC)
comprises a heterogeneous group of cancer with diverse genetic and molecular alterations …
comprises a heterogeneous group of cancer with diverse genetic and molecular alterations …
[HTML][HTML] The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure
and the development of acquired resistance is the rule rather than the exception. CDK4/6 …
and the development of acquired resistance is the rule rather than the exception. CDK4/6 …
[HTML][HTML] The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors
W Liu, B Zhang, D Zhang, F Guo, K Ye, L Zhu… - Cell death & …, 2022 - nature.com
Renal cell carcinoma (RCC) is a kind of malignant tumor originating from the renal tubular
epithelium. Approximately 30% of patients with renal cancer are found to have metastasis …
epithelium. Approximately 30% of patients with renal cancer are found to have metastasis …